Peapod Lane Capital LLC Acquires Shares of 108,853 iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Peapod Lane Capital LLC bought a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 108,853 shares of the company’s stock, valued at approximately $836,000.

A number of other institutional investors have also recently modified their holdings of ITOS. State Street Corp boosted its stake in iTeos Therapeutics by 21.9% in the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after purchasing an additional 211,452 shares in the last quarter. Algert Global LLC raised its holdings in iTeos Therapeutics by 92.0% in the third quarter. Algert Global LLC now owns 256,139 shares of the company’s stock worth $2,615,000 after buying an additional 122,730 shares during the last quarter. Readystate Asset Management LP lifted its stake in shares of iTeos Therapeutics by 97.2% in the third quarter. Readystate Asset Management LP now owns 169,819 shares of the company’s stock worth $1,734,000 after buying an additional 83,700 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of iTeos Therapeutics during the third quarter valued at approximately $306,000. Finally, Jacobs Levy Equity Management Inc. increased its position in shares of iTeos Therapeutics by 16.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 205,863 shares of the company’s stock valued at $2,102,000 after acquiring an additional 29,549 shares in the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

iTeos Therapeutics Trading Up 1.5 %

NASDAQ:ITOS opened at $7.29 on Thursday. The company has a market cap of $266.30 million, a PE ratio of -2.31 and a beta of 1.38. The company has a 50 day simple moving average of $7.69 and a two-hundred day simple moving average of $10.46. iTeos Therapeutics, Inc. has a 12 month low of $7.06 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.13. Research analysts forecast that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ITOS. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, January 16th. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Friday, January 10th.

Insiders Place Their Bets

In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of iTeos Therapeutics stock in a transaction on Tuesday, November 19th. The stock was acquired at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now owns 65,429 shares in the company, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 12.50% of the company’s stock.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.